The resident, identified as R9 in the inspection report, required substantial assistance with daily activities and had a care plan specifically targeting seizure prevention. Laboratory results from October showed the resident's phenytoin levels had already dropped to 9.5 micrograms per milliliter, below the normal range of 10 to 20.
On October 22 at 2:17 pm, inspectors watched Licensed Practical Nurse AA administer both Dilantin and the house supplement to R9 simultaneously. The facility's medication schedule called for Dilantin at 9:00 am, 2:00 pm, and 9:00 pm, with the high-protein house supplement at 10:00 am and 2:00 pm.
The timing created a direct conflict twice daily.
The facility's pharmacy consultant told inspectors that Dilantin should be given one hour before or two hours after the high-protein supplement to avoid interaction. She confirmed the current schedule violated this requirement, with both the 2:00 pm Dilantin dose and 2:00 pm supplement administered together.
Records showed this pattern continued for weeks. The medication administration record documented both the seizure medication and supplement as given on schedule from October 1 through October 22, with the supplement showing 50 to 100 percent consumption.
The Director of Nursing acknowledged that the pharmacy made medication scheduling recommendations but said no safety alerts were in place for contraindications. The administrator explained that medication schedules were entered by nurses or nurse practitioners, with pharmacy recommendations available.
The facility's own policy required staff to review medications for special precautions and perform needed evaluations before administration. The policy stated medications should be given as prescribed by providers.
Yet the scheduling conflict persisted despite R9's documented seizure risk and declining drug levels.
Phenytoin, marketed as Dilantin, prevents and controls seizures by stabilizing electrical activity in the brain. When protein interferes with absorption, blood levels drop below therapeutic ranges, potentially triggering breakthrough seizures.
The resident's October laboratory results showed phenytoin levels at 9.5 micrograms per milliliter, just below the minimum effective range. The medication administration record showed R9 received 50 milligrams three times daily through chewable tablets.
The supplement contained high protein levels that bind with phenytoin in the digestive system, reducing the amount absorbed into the bloodstream. This interaction is well-documented in pharmaceutical literature and should trigger automatic scheduling adjustments.
The pharmacy consultant confirmed the interaction during her October 22 interview, stating that pharmacy labels should provide instructions for medications with food or drug interactions. She verified that the house supplement qualified as a high-protein product requiring separation from Dilantin administration.
The facility's care plan for R9, dated August 20, established a goal of preventing seizure activity through the next review date. The plan acknowledged R9's seizure risk and the importance of maintaining therapeutic medication levels.
Despite this documented risk, the medication schedule remained unchanged for weeks. The October 1 through October 22 administration records showed consistent timing conflicts, with both medications given as scheduled without adjustment for the known interaction.
Inspectors classified the violation as having minimal harm or potential for actual harm, but noted the deficient practice placed R9 at risk of medical complications from reduced medication absorption.
The Director of Nursing's statement that no safety alerts existed for contraindications suggested systemic gaps in the facility's medication management protocols. The administrator's explanation that scheduling depended on individual nurse or nurse practitioner decisions indicated a lack of centralized oversight for drug interactions.
R9's case illustrated how seemingly routine medication administration can become dangerous when staff fail to recognize and prevent known drug interactions. The resident's declining phenytoin levels, combined with continued simultaneous administration of the interfering supplement, created ongoing risk for breakthrough seizures.
The facility's policy required reviewing medications for special precautions, but the practice observed by inspectors showed this review either didn't occur or failed to identify the obvious scheduling conflict.
For a resident already requiring substantial assistance with daily activities, seizure breakthrough could create additional complications and safety risks. The medication error continued for at least three weeks before inspectors identified the problem during their October visit.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Savannah Post Acute LLC from 2025-11-18 including all violations, facility responses, and corrective action plans.